Tài liệu Báo cáo y học: "Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the

The chemotherapeutic treatment of solid tumors has progressed extensively since the development of the first platinum agent, cisplatin (CDDP), in the 1970s [1]. Although the precise mechanisms by which CDDP exerts its cytotoxic action has not been fully elucidated, its effects on solid tumors have encour-aged CDDP-based clinical protocols, and also the de-velopment of new platinum agents [1, 2]. Today, the leading agents include CDDP, carboplatin (CBDCA), and oxaliplatin (L-OHP), which share some structural similarities, but differ in therapeutic use and safety profiles.